J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B

 
• By Joseph Haas

The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

More from Deals

More from Business